Recipients of kidney transplants from HCV-RNA–positive deceased donors had 5-year mean allograft survival that was not statistically different from HCV-RNA–negative kidney recipients during the direct-acting antiviral era JAMA 2022
Source: Sensitization in Transplantation: Assessment of Risk (STAR). 2017 Working Group Meeting Report.